Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
Jacquelyn A. Hank, Paul M. Sondel(University of Wisconsin–Madison), Barbara M. Mueller(Torrey Pines Institute For Molecular Studies), N K Cheung(Memorial Sloan Kettering Cancer Center), Jean E. Surfus, Ralph A. Reisfeld, Randy Robinson(AbbVie (United States))
PubMed
September 1, 1990
Cited by 156
Related Papers
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
|New England Journal of Medicine|2010|1.8k
Integrin activation controls metastasis in human breast cancer
|Proceedings of the National Academy of Sciences|2001|580
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
|Journal of Clinical Oncology|1987|417